Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
| ▸ | CA2 | P00918 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6381209 | 0.92 | CA1 (0.61) | CA1CA2POLBKMT2AMEN1 | |
| SCHEMBL148633 | 0.87 | KMT2A (0.58) | CA1CA2POLBKMT2AMEN1 | |
| SCHEMBL6788690 | 0.85 | POLB (0.68) | CA1CA2POLBKMT2AMEN1 | |
| SCHEMBL11444921 | 0.83 | LMNA (0.61) | CA1CA2POLBKMT2AMEN1 | |
| SCHEMBL6376716 | 0.83 | MEN1 (0.79) | CA1CA2POLBKMT2AMEN1 | |
| SCHEMBL248400 | 0.82 | CA1 (0.79) | CA1CA2KMT2AMEN1L3MBTL1 | |
| SCHEMBL30738251 | 0.82 | CA1 (0.79) | CA1CA2KMT2AMEN1L3MBTL1 | |
| SCHEMBL6377354 | 0.82 | MEN1 (0.66) | CA1CA2POLBKMT2AMEN1 | |
| SCHEMBL147264 | 0.82 | SMN1; SMN2 (0.57) | CA1CA2POLBKMT2AMEN1 | |
| SCHEMBL6378383 | 0.80 | MEN1 (0.79) | CA1CA2KMT2AMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059026-A1 | ANTIMICROBIAL AGENTS | ZYX, Q6ZSR9, ZC3HAV1L | CA1 3802/4885CA2 1379/4885POLB 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.